skip to Main Content

HCC SUMMIT 2018

01 - 03 March

Geneva, Switzerland
Alejandro-Forner

Dr Alejandro Forner, Spain

Dr Alejandro Forner achieved his medical degree at the University “Miguel Hernández”, Alicante, Spain, in June 1999, obtaining the Extraordinary Licensure Award for the best medical school academic expedient. He obtained the Board certification in Gastroenterology and Hepatology in the Liver and Gastroenterology Unit, Hospital Clinic, Barcelona (2001-2005) and since 2005, he works in the Barcelona Clinic Liver Cancer Group (BCLC) group, Liver Unit, Hospital Clinic Barcelona.

His clinical activity is based on the care of cirrhotic patients with hepatocellular carcinoma and his investigational fields are the early diagnosis (doctoral thesis), role of liver transplantation in hepatocellular carcinoma and the treatment of advanced hepatocellular carcinoma. He acts as reviewer for the most cited peer-reviewed journals in Hepatology and Oncology (Hepatology, Gut, Journal of Hepatology, Liver Transplantation, Lancet Oncology), and is member of the Editorial Board of Lancet Oncology and Associate Editor in Liver International. Furthermore, he is member of the Scientific Committee of the Spanish Societies of Liver Disease (AEEH) and Digestive Disease (SEPD). Finally, he has authored several originals, editorials and reviews about HCC with an accumulated impact factor superior to 500, and he is the first author of the Spanish Guidelines for HCC management.

Read more
Peter-Galle

Prof. Peter Galle, Germany

Prof. Peter Galle (MD, PhD) majored in internal medicine at the Universities of Berlin and Marburg/Germany, Hammersmith Hospital, London/UK and University of Texas/USA and received his M.D. degree from Marburg University and Ph.D. degree from Heidelberg University.

Initially he held a position as postdoctoral fellow in Molecular Biology at the Centre for Molecular Biology Heidelberg working on the replication of hepatitis B viruses. Afterwards he completed his residency in Internal Medicine and Gastroenterology at the University Hospital of Heidelberg. In 1998 he became Director of the I. Medical Department in Mainz and from 2005 – 2008 he hold the CEO position of Mainz University Hospital.

He is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), served as Co-editor for the Journal of Hepatology and is on the Editorial Boards of several other Journals. He served as congress president of the German Society for Digestive Diseases (DGVS) in 2014. He was member of the Executive Board and President of the International Liver Cancer Association (ILCA).

His research has focused on elucidating important aspects of apoptotic cell death in the liver, immune escape of tumour cells and on clinical and molecular aspects of hepatocellular carcinoma. He was awarded several prizes, amongst others the prestigious Tannhauser award, the highest prize of the German Society for Digestive Diseases. He has published more than 500 peer-reviewed papers.

Read more
Zucman-Rossi

Prof. Jessica Zucman-Rossi, France

Prof. Jessica Zucman-Rossi and her team develop basic genomic approaches based on human tumors analyses to identify new mechanisms of tumorigenesis in the liver and to transfer this knowledge into biomarkers and therapeutic targets that could be introduced in clinical care.

Their general strategy is based on the omic’s analyses of large cohorts of patients with liver tumors (benign and malignant), mesothelioma and clear cell renal carcinoma. In particular, the group was pioneer in the elucidation of the molecular classification of benign and malignant liver tumors. Recently, the team has identified new genomic alterations and mechanisms of carcinogenesis with the frequent involvement of TERT promoter mutations as an early event during hepatocyte malignant transformation. They also identified new risk factors of hepatocellular carcinoma with the identification of AAV2 integration activating oncogenes in patients without cirrhosis.

The team also aims to translate genomic findings into the clinics to improve surveillance, diagnosis, prognosis, treatment and follow-up of the patients with benign and malignant tumors.

Read more